ClinicalTrials.gg
CompletedNCT00240929Updated Nov 15, 2010

A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)

A Phase 2 interventional study of MEDI-493 in -Unhealthy Children With a History of Prematurity, sponsored by MedImmune LLC. Completed at 1 site in United States. Open to participants aged 5 Months to 6 Months. Per ClinicalTrials.gov, last updated 2010-11-15.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
5 Months to 6 Months
Sex
All
01

Study summary

A total of 150 children who meet the entry criteria will be randomized 1:1 to receive one of the following treatment sequence A or B.

Read the detailed description

Phase II, Double-blind, two-period, cross-over study to be conducted at 20 sites the U.S. A total of 150 children who meet the entry criteria will be randomized 1:1 to receive one of the following treatment sequence: Sequence A (single dose of the liquid formulation on Study Day 0 and a single dose of the lyophilized formulation on Study Day 30) or Sequence B (single dose of the lyophized forumation on Study Day 0 and single dose of the liquid formulation on Study Day 30). Children will be followed for adverse events through 30 days after each injection of study drug and will have blood collected for determination of palivizumab concentrations in serum.

02

Conditions studied

  • -Unhealthy Children With a History of Prematurity
03

In context

Lead sponsor

MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.

Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.

First submitted before MedImmune LLC became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Months to 6 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The child must have been born at greater than or equal to 35 weeks gestation and be greater than or equal to 6 months of age at the time of randomization (child must be randomized on or before their 6-month birthday)
  • The child's parent or legal guardian must provide written ; and
  • The child must be able to complete the follow-up visits on Study Days 30 and 60 within the protocol specified windows (±2 days)
  • Parent/legal guardian of patient has available telephone access.

Exclusion criteria

Exclusion Criteria:

  • Be hospitalized;
  • Birth hospitalization > 6 weeks duration;
  • Be receiving mechanical ventilation at the time of study entry (including CPAP);
  • Bronchopulmonary dysplasia (BPD), defined as history of prematurity and associated chronic lung disease with oxygen requirement for >28 days;
  • Congenital heart disease (CHD). (Children with medically or surgically corrected [closed] patent ductus arteriosus and no other CHD may be enrolled.)
  • Known renal impairment, hepatic dysfunction, chronic seizure disorder, or immunodeficiency;
  • Any of the following laboratory findings in blood obtained within 7 days prior to study entry:
  • BUN or creatinine >1.5´ the for age
  • (SGOT) or ALT (SGPT) >1.5´ the upper limit of normal for age
  • \<9.0 gm/dL
  • white blood cell count \<4,000 cells/mm3
  • count \<110,000 cells/mm3
  • Acute illness or progressive clinical disorder;
  • History of recent difficult venous access;
  • Active infection, including acute RSV infection;
  • Previous reaction to IGIV, blood products, or other foreign proteins;
  • Received within the past 120 days or currently receiving IGIV, other immunoglobulin products, or any agents;
  • Have ever received palivizumab;
  • Currently participating in any investigational study; or
  • Previously participated in any investigational study of RSV vaccines or monoclonal antibodies.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (actual)

Interventions

  • Active Comparator

    Also known as: Synagis

06

What researchers measure

Primary outcomes

  1. adverse events through 30 days after each injection of study drug and will have blood collected for determination of palivizumab concentrations in serum.

    Time frame: Day 30

Secondary outcomes

  1. Adverse events and serious adverse events for 30 days after each injection of study drug.

    Time frame: Day 30

07

Study locations

1 site
  • Packard Children's Hospital at Stanford
    Palo Alto, California 94304, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2002 and a completion of Apr 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2005
First posted
Oct 18, 2005
Start
Sep 2002
CompletionActual
Apr 2003
Last update
Nov 15, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00240929
Lead sponsor
MedImmune LLC
First posted
Oct 18, 2005
Start date
Sep 2002
Completion
Apr 2003
Last update
Nov 15, 2010

Study contacts

Genevieve Losonsky, M.D.
study director · "Unaffliliated"
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palivizumab

Start the discussion